07:11 EDT Lexeo sees cash, equivalents sufficient to fund operations into 2027
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences
- Bernard Davitian to Exit Board of Lexeo Therapeutics
- Lexeo announces license agreement to accelerate development of LX2006
- Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy